Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

AIM ImmunoTech Inc. (AIM) stock profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug composed of large macromolecular double-stranded ribonucleic acid molecules for treating chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for treating genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Key facts

SymbolAIM
ExchangeAMEX
SectorHealthcare
IndustryBiotechnology
CEOThomas K. Equels
Employees19
HeadquartersOcala, FL, US
IPO1995-11-02
Websiteaimimmuno.com

Explore AIM on Vantafin

  • AIM ImmunoTech Inc. Overview
  • AIM ImmunoTech Inc. Financials
  • AIM ImmunoTech Inc. News
  • AIM ImmunoTech Inc. Events
  • AIM ImmunoTech Inc. SEC filings
  • AIM ImmunoTech Inc. Insider transactions
  • AIM ImmunoTech Inc. Transcripts

Frequently asked questions

What does AIM ImmunoTech Inc. (AIM) do?
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug composed of large macromolecular double-stranded ribonucleic acid molecules for treating chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for treating genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Where is AIM stock listed?
AIM ImmunoTech Inc. trades under the ticker AIM on AMEX.
How can I research AIM's financials and filings?
Vantafin provides AIM ImmunoTech Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the AIM profile.